Yang YN, Wang LS, Dang YQ, Ji G. Evaluating the efficacy of immunotherapy in gastric cancer: Insights from immune checkpoint inhibitors. World J Gastroenterol 2024; 30(32): 3726-3729 [PMID: 39221068 DOI: 10.3748/wjg.v30.i32.3726]
Corresponding Author of This Article
Guang Ji, MD, PhD, Professor, Institute of Digestive Diseases, Longhua Hospital, China-Canada Center of Research for Digestive Diseases, Shanghai University of Traditional Chinese Medicine, No. 725 South Wanping Road, Xuhui District, Shanghai 200032, China. jiliver@vip.sina.com
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Aug 28, 2024; 30(32): 3726-3729 Published online Aug 28, 2024. doi: 10.3748/wjg.v30.i32.3726
Evaluating the efficacy of immunotherapy in gastric cancer: Insights from immune checkpoint inhibitors
Yu-Nuo Yang, Li-Sheng Wang, Yan-Qi Dang, Guang Ji
Yu-Nuo Yang, Yan-Qi Dang, Guang Ji, Institute of Digestive Diseases, Longhua Hospital, China-Canada Center of Research for Digestive Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
Li-Sheng Wang, Department of Biochemistry, University of Ottawa, Ottawa K1H 8M5, ON, Canada
Co-corresponding authors: Yan-Qi Dang and Guang Ji.
Author contributions: Ji G and Dang YQ designed research; Yang YN and Wang LS wrote the paper. We have designated two corresponding authors for this paper to leverage their complementary expertise and ensure comprehensive guidance throughout the research process. Dang YQ possesses profound knowledge in diseases of the digestive system, bringing valuable insights into the theoretical framework and methodology. Ji G, on the other hand, provides a deep understanding of theoretical frameworks and has been instrumental in interpreting our results within the broader context of the field. Their combined efforts have been instrumental in shaping the study's direction and ensuring its scientific rigor. By having both as corresponding authors, we aim to facilitate effective communication and collaboration, ensuring the highest quality and impact of our research.
Supported byNational Nature Science Foundation of China, No. 82320108022; Shanghai Rising-Star Program, No. 21QA1409000; and Shanghai Frontier Research Base of Disease and Syndrome Biology of Inflammatory Cancer Transformation, No. 2021KJ03-12.
Conflict-of-interest statement: All the authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Guang Ji, MD, PhD, Professor, Institute of Digestive Diseases, Longhua Hospital, China-Canada Center of Research for Digestive Diseases, Shanghai University of Traditional Chinese Medicine, No. 725 South Wanping Road, Xuhui District, Shanghai 200032, China. jiliver@vip.sina.com
Received: February 28, 2024 Revised: August 6, 2024 Accepted: August 9, 2024 Published online: August 28, 2024 Processing time: 180 Days and 20.7 Hours
Abstract
The emergence of immunotherapy, particularly immune checkpoint inhibitors (ICIs), represents a groundbreaking approach to treating gastric cancer (GC). However, the prognosis of GC patients receiving ICI treatment is influenced by various factors. This manuscript identified sarcopenia and myosteatosis as inde-pendent prognostic factors impacting the outcomes of GC patients treated with ICIs. Additionally, this study introduced a visual predictive model to estimate the prognosis of GC patients. If confirmed by further studies, this observation could provide valuable insights to propel the advancement of personalized clinical medicine and the integration of precision medicine practices.
Core Tip: This study delved into the determinants influencing the efficacy of immune checkpoint inhibitor (ICI) therapy in gastric cancer. Employing COX regression analysis, it crafted a prediction model aimed at enhancing the efficiency and simplicity of evaluating the suitability of immunotherapy. These findings offer novel perspectives for the judicious utilization of ICIs, contributing to improved treatment decision-making and patient care.
